triptonide has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Liu, Y; Lu, W; Meng, M; Qi, J; Qiao, Y; Xu, P; Zhang, M; Zhao, Z; Zhou, Q; Zhou, Z | 1 |
| Chen, J; Cui, X; Cui, Y; Gao, B; Giuliano, AE; Han, B; Hao, J; Zhang, X | 1 |
2 other study(ies) available for triptonide and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Mice; Nuclear Proteins; Oncogene Proteins; Receptor, Notch1; Triple Negative Breast Neoplasms; Triterpenes; Twist-Related Protein 1 | 2021 |
Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Humans; Mice; Molecular Structure; Neoplastic Stem Cells; Snail Family Transcription Factors; Triple Negative Breast Neoplasms; Triterpenes; Xenograft Model Antitumor Assays | 2021 |